JP Morgan, Bank of America/Merrill Lynch and Goldman Sachs are among the investment banks underwriting biotech companies this year, Securities and Exchange Commission filings show. Other investors include Needham & Co., BMO Capital Markets, Stifel Nicolaus and Oppenheimer. The financing of Regulus Therapeutics, which does not have a drug in clinical trials, shows that Wall Street may be willing to take more risks on biotech, Luke Timmerman writes.

Full Story:

Related Summaries